S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
The Latest: After delays, Brazil approves two virus vaccines
Violent youth protests hit Tunisia amid economic turmoil
The Latest: Slovakia wants tests for nearly all in nine days
N. Korea's parliament rubber stamps new development plans
Russian cargo ship sinks in the Black Sea, rescue underway
Richard Branson's Virgin Orbit reaches space on 2nd try
Cargo ship sinks in the Black Sea; 3 dead, 6 rescued
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
The Latest: After delays, Brazil approves two virus vaccines
Violent youth protests hit Tunisia amid economic turmoil
The Latest: Slovakia wants tests for nearly all in nine days
N. Korea's parliament rubber stamps new development plans
Russian cargo ship sinks in the Black Sea, rescue underway
Richard Branson's Virgin Orbit reaches space on 2nd try
Cargo ship sinks in the Black Sea; 3 dead, 6 rescued
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
The Latest: After delays, Brazil approves two virus vaccines
Violent youth protests hit Tunisia amid economic turmoil
The Latest: Slovakia wants tests for nearly all in nine days
N. Korea's parliament rubber stamps new development plans
Russian cargo ship sinks in the Black Sea, rescue underway
Richard Branson's Virgin Orbit reaches space on 2nd try
Cargo ship sinks in the Black Sea; 3 dead, 6 rescued
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
The Latest: After delays, Brazil approves two virus vaccines
Violent youth protests hit Tunisia amid economic turmoil
The Latest: Slovakia wants tests for nearly all in nine days
N. Korea's parliament rubber stamps new development plans
Russian cargo ship sinks in the Black Sea, rescue underway
Richard Branson's Virgin Orbit reaches space on 2nd try
Cargo ship sinks in the Black Sea; 3 dead, 6 rescued
Log in
ASX:EMD

Emyria Limited (EMD.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.06
MA: A$0.06▼
A$0.06
52-Week Range N/A
Volume471,333 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Emyria Limited, a healthcare technology and services company, operates a network of specialist medical clinics. Its medical clinics offer treatments, such as cannabinoid-based medicines. As of July 31, 2020, the company operated four patient-focused medical clinics. It has a partnership agreement with Mind Medicine Australia to co-develop a gold-standard and data-driven clinical model for the safe provision of psychedelic-assisted therapies in Australia. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was founded in 2018 and is based in West Leederville, Australia.

MarketRank™

Overall MarketRank™

0.60 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange ASX
Industry Health Information Services
Sub-IndustryN/A
SectorMedical
Current SymbolASX:EMD
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.emeraldclinics.com.au
Phone61 8 6559 2800
EmployeesN/A

Debt

Debt-to-Equity Ratio16.15
Current Ratio3.83
Quick Ratio3.77

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.01 million
Price / Sales0.00
Cash FlowN/A
Price / Cash Flow6.67
Book ValueA$0.02 per share
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive EMD News and Ratings via Email

Sign-up to receive the latest news and ratings for EMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Emyria Limited (EMD.AX) (ASX:EMD) Frequently Asked Questions

What stocks does MarketBeat like better than Emyria Limited (EMD.AX)?

Wall Street analysts have given Emyria Limited (EMD.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Emyria Limited (EMD.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Emyria Limited (EMD.AX)'s key competitors?

Some companies that are related to Emyria Limited (EMD.AX) include 1st Group Limited (1ST.AX) (1ST), Alcidion Group Limited (ALC.AX) (ALC), Cann American (CNNA), CannaOne Technologies (CNONF), CloudMD Software & Services (DOCRF), CloudMD Software & Services Inc. (DOC.V) (DOC), Cogstate Limited (CGS.AX) (CGS), Corum Group Limited (COO.AX) (COO), EGF Theramed Health (EVAHF), eWellness Healthcare (EWLL), Global Health Limited (GLH.AX) (GLH), ICS Global Limited (ICS.AX) (ICS), Jayex Healthcare Limited (JHL.AX) (JHL), M3 (MTHRF) and Mach7 Technologies Limited (M7T.AX) (M7T).
View all of EMD's competitors.

Who are Emyria Limited (EMD.AX)'s key executives?

Emyria Limited (EMD.AX)'s management team includes the following people:
  • Dr. Stewart James Washer B.Sc., BSc (Hons), Ph.D., Exec. Chairman (Age 50, Pay $259.94k)
  • Dr. Michael Winlo, MD & Director
  • Ms. Su-Mei Sain, Chief Financial Officer
  • Mr. Adam James, Chief Operating Officer
  • Dr. Alistair Vickery, Exec. Medical Director & Director
  • Mr. Simon Robertson C.A., B.Bus, M Appl. Fin, CA, Company Sec.

What is Emyria Limited (EMD.AX)'s stock symbol?

Emyria Limited (EMD.AX) trades on the ASX under the ticker symbol "EMD."

How big of a company is Emyria Limited (EMD.AX)?

Emyria Limited (EMD.AX) has a market capitalization of $0.00 and generates $1.01 million in revenue each year.

What is Emyria Limited (EMD.AX)'s official website?

The official website for Emyria Limited (EMD.AX) is www.emeraldclinics.com.au.

How can I contact Emyria Limited (EMD.AX)?

The company can be reached via phone at 61 8 6559 2800.

This page was last updated on 1/18/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.